Fresh analysis indicates that people who stop using popular GLP-1 drugs like semaglutide or tirzepatide may regain lost weight far faster than those who end conventional diet and exercise regimens.
Research printed in a prominent medical journal points out that while overweight people often shed about a fifth of their total mass while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month after stopping.
"People purchasing such medications should be informed of the danger of rapid weight regain when the medication is stopped," stated lead investigator Dr. Susan Jebb.
This pace of recovery suggests a reversion to original weight in about 18 months.
Weighing Therapies
The analysis, which examined dozens of studies involving thousands of patients, compared the outcomes of GLP-1 agonists with other pills.
Researchers note that people who shed pounds through diet and exercise generally experience a more gradual creep back—approximately 0.1 kg a month—post-intervention.
Explaining the Fast Regain
Nutrition scientists suggest the way of the injections is key to understanding the amplified regain.
These medications imitate a body's own chemical called GLP-1, which controls feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than normal may cause the body to produce less of its endogenous hormone, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' means hunger is unsuppressed, making overeating a significant risk."
An Ongoing Condition?
Health authorities recommend the injections for people with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals contend that, given the significant potential of relapse, the therapy should be considered long-term.
This view is reinforced by drug manufacturers, who say that the findings "emphasize the chronic character of excess weight," similar to managing diseases like diabetes.
Patient Experiences
Individuals who have stopped the jabs describe a intense return of hunger.
"I experienced something that goes on and you're instantly ravenous," said a patient.
This difficulty is compounded if individuals have not established sustainable lifestyle or habit modifications during therapy.
Widespread Adoption
Survey data indicate that millions of people in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Adoption is more common among women than males.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the medications through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while these medications are effective agents for shedding pounds, they are not a standalone fix and lasting health benefits hinges on combined behavioural changes.
